Eagle’s Eye View: Can Rhythm Control Improve Tricuspid Regurgitation?
In this week’s View, Dr. Eagle examines the role of rhythm control in improving moderate-to-severe and severe secondary tricuspid valve regurgitation. He then explores evidence showing that blood pressure reduction can deliver comparable cardiovascular benefits for patients with chronic kidney disease (CKD). Another study reviewed in this episode assesses the outcomes of continuing versus switching direct oral anticoagulant (DOAC) therapy in patients with atrial fibrillation (AFib) who experience breakthrough stroke. Finally, Dr. Eagle summarizes the AVANTE-GUARD trial, which evaluates pulsed field ablation as a first-line treatment for patients with persistent AFib.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Anticoagulation Management and Atrial Fibrillation, EP Basic Science, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure
Keywords: EaglesEyeView, Tricuspid Valve, Tricuspid Valve Insufficiency, Atrial Fibrillation, Renal Insufficiency, Chronic, Antihypertensive Agents, Diabetes Mellitus, Blood Pressure, Heart Failure, Anticoagulants, Ischemic Stroke, Anti-Arrhythmia Agents, Tachycardia, Thrombosis
